Caribou Biosciences Inc (NASDAQ: CRBU) Stock: More Upside Ahead?

In the last trading session, 1.03 million Caribou Biosciences Inc (NASDAQ:CRBU) shares changed hands as the company’s beta touched 2.28. With the company’s per share price at $1.98 changed hands at $0.04 or 2.06% during last session, the market valuation stood at $178.91M. CRBU’s last price was a discount, traded about -320.71% off its 52-week high of $8.33. The share price had its 52-week low at $1.50, which suggests the last value was 24.24% up since then. When we look at Caribou Biosciences Inc’s average trading volume, we note the 10-day average is 0.84 million shares, with the 3-month average coming to 1.41 million.

Analysts gave the Caribou Biosciences Inc (CRBU) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRBU as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Caribou Biosciences Inc (NASDAQ:CRBU) trade information

Instantly CRBU was in green as seen at the end of in last trading. With action -4.35%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -65.45%, with the 5-day performance at -4.35% in the red. However, in the 30-day time frame, Caribou Biosciences Inc (NASDAQ:CRBU) is -5.26% down. Looking at the short shares, we see there were 11.63 million shares sold at short interest cover period of 12.1 days.

The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 34.0% from its current market value. According to analyst projections, CRBU’s forecast low is 3 with 3 as the target high. To hit the forecast high, the stock’s price needs a -51.52% plunge from its current level, while the stock would need to soar -51.52% for it to hit the projected low.

Caribou Biosciences Inc (CRBU) estimates and forecasts

Data shows that the Caribou Biosciences Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -61.48% over the past 6 months, a -27.54% in annual growth rate that is considerably lower than the industry average of 17.70%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -37.16%. The 2024 estimates are for Caribou Biosciences Inc earnings to decrease by -28.53%, but the outlook for the next 5-year period is at 14.50% per year.

CRBU Dividends

Caribou Biosciences Inc is expected to release its next quarterly earnings report in October.

Caribou Biosciences Inc (NASDAQ:CRBU)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 10.05% of Caribou Biosciences Inc shares while 62.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 69.78%. There are 62.76% institutions holding the Caribou Biosciences Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 7.7801% of the shares, roughly 6.95 million CRBU shares worth $11.39 million.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.0891% or 4.54 million shares worth $7.45 million as of 2024-06-30.